Crohns Disease Market

Rising prevalence of inflammatory bowel disorder (IBD) to propel market growth

Inflammation and irritation of the digestive tract are symptoms of Crohn's disease, a kind of Inflammatory Bowel Disease (IBD). While this condition can affect any section of the gastrointestinal tract, including the mouth and the stomach, it most frequently affects the small intestine and colon. The market for Crohn's disease is anticipated to expand rapidly due to factors including the rise in inflammatory bowel disorders (IBD) and the number of Crohn's disease patients.

For instance, a disease-death model based on data available was constructed to forecast the future prevalence of IBD in Asia, and Iran in particular, from 2017 to 2035, according to an article published by the Journal BMC Gastroenterology in May 2021. 

The study predicted a 2.5-fold increase in prevalence for Iran with 69 thousand cases in 2035 compared to 2020, a 2.3-fold increase for North Africa and the Middle East with 220 thousand cases, a quadrupling of the prevalence for India with 2.2 million cases, a 1.5-fold increase for East Asia region with 4.5 million cases, and a 1.6-fold increase for high-income Asia-Pacific and Southeast Asia regions with 183 and 199 thousand cases, respectively. Thus, this factor is driving the market CAGR for Crohn’s disease.

However, another important element driving the market growth of the Crohn's disease is the creation of innovative and potent treatment options to treat the illness's symptoms. For instance, at the Crohn's & Colitis Congress held in January 2018, researchers from the University of Washington Medicine presented a study that produced an antibiotic that demonstrated a four-fold better response to the inflammation of the intestine among patients with Crohn's disease as compared to the currently available therapies. Thus, it is anticipated that this aspect will accelerate Crohn’s disease market revenue globally.

The Global Crohn's Disease Market Industry is projected to experience a compound annual growth rate (CAGR) of 3.72% from 2025 to 2035. This growth trajectory indicates a robust demand for treatment options as the prevalence of Crohn's disease continues to rise. The market is expected to reach a valuation of 17.8 USD Billion by 2035, driven by advancements in therapies, increasing healthcare expenditures, and growing awareness. These projections underscore the potential for sustained growth in the Global Crohn's Disease Market Industry, highlighting the importance of ongoing research and development efforts.

There is a marked increase in awareness and education regarding Crohn's disease, which is positively impacting the Global Crohn's Disease Market Industry. Campaigns aimed at educating the public about the symptoms, risks, and management of Crohn's disease are becoming more prevalent. This heightened awareness leads to earlier diagnosis and treatment, which is crucial for effective disease management. Additionally, healthcare professionals are receiving more training on the latest treatment protocols, further enhancing patient care. As awareness continues to grow, the demand for treatment options is expected to rise, thereby propelling the Global Crohn's Disease Market Industry forward.

Innovations in treatment modalities are significantly influencing the Global Crohn's Disease Market Industry. The introduction of biologic therapies and targeted medications has transformed the management of Crohn's disease, offering patients more effective options. These advancements not only improve patient outcomes but also contribute to the market's expansion, with projections indicating a growth to 17.8 USD Billion by 2035. The ongoing research and development efforts by pharmaceutical companies are likely to yield new therapies, which may further enhance the treatment landscape. As a result, the Global Crohn's Disease Market Industry is positioned for sustained growth driven by these advancements.

The Global Crohn's Disease Market Industry is benefiting from rising healthcare expenditures across various regions. Governments and private sectors are investing more in healthcare infrastructure, which includes the management of chronic diseases like Crohn's. This trend is particularly evident in developed nations, where healthcare budgets are expanding to accommodate advanced treatments and patient care. The increasing financial commitment towards healthcare is expected to facilitate better access to medications and therapies, thereby supporting the growth of the market. As healthcare spending continues to rise, the Global Crohn's Disease Market Industry is likely to experience a corresponding increase in demand for effective treatment solutions.

The Global Crohn's Disease Market Industry is witnessing a notable increase in the prevalence of Crohn's disease, which is a chronic inflammatory bowel disease. As of 2024, the market is valued at 11.9 USD Billion, reflecting the growing number of diagnosed cases. Factors contributing to this rise include genetic predisposition, environmental triggers, and lifestyle changes. The increasing awareness and improved diagnostic techniques further enhance the identification of this condition. Consequently, healthcare systems are compelled to allocate more resources towards treatment and management, thereby driving growth in the Global Crohn's Disease Market Industry.

The Global Crohn's Disease Market Industry is experiencing favorable regulatory environments that support the approval of new drugs and therapies. Regulatory agencies are streamlining the approval process for innovative treatments, which encourages pharmaceutical companies to invest in research and development. This supportive framework is essential for bringing new therapies to market more quickly, thereby addressing the unmet needs of patients with Crohn's disease. As more effective treatments become available, the market is likely to expand, reflecting the positive impact of regulatory support on the Global Crohn's Disease Market Industry.

By region, the study provides the market insights for Crohn’s disease into North America, Europe, Asia-Pacific and Rest of the World. North America Crohn’s disease market accounted for USD 5.1 billion in 2022 with a share of around 45.80% and is expected to exhibit a significant CAGR growth during the study period due to rising rates of Crohn's disease and increased awareness of the various therapies. According to CDC data, about 3 million people in the USA alone have been diagnosed with Crohn's disease. A sizable share of the patient population is from Canada.

Better medical literacy and a more developed healthcare infrastructure are factors in this region's market expansion.

Further, the major countries studied in the market report for Crohn’s disease are: The U.S, Canada, Germany, France, UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.

Figure 3: CROHN’S DISEASE MARKET SHARE BY REGION 2022 (%)

Source: Secondary Research, Primary Research, Market Research Future Database and Analyst Review

Europe Crohn’s disease market accounts for the second-largest market share as more patients are given this diagnosis and look for available treatments. The chief causes of the disease are currently thought to be dietary patterns and sedentary lifestyles. However, good medical research, availability of better drugs and treatment therapies are helping in market expansion in this region. Further, the UK market for Crohn’s disease held the largest market share, and the Germany market of Crohn’s disease was the fastest growing market in the region.

Asia Pacific market for Crohn’s disease is expected to grow at the fastest CAGR from 2022 to 2030 due to patients' and their families' rising knowledge of the therapies that are available, as well as the expanding economies of nations like China and India. By 2035, it is anticipated that the prevalence of this disease would have quadrupled in this area. In order to treat the increasing number of patients, it will be advantageous to invest in bolstering the health care infrastructure.

Moreover, China market of Crohn’s disease held the largest market share, and the India market of Crohn’s disease was the fastest growing market in the region.

Major market players are spending a lot of money on R&D to increase their product lines, which will help the market growth of Crohn’s disease even more. Market participants are also taking a range of strategic initiatives to grow their worldwide footprint, with key market developments such as new product launches, contractual agreements, mergers and acquisitions, increased investments, and collaboration with other organizations. Competitors in the Crohn’s disease industry must offer cost-effective items to expand and survive in an increasingly competitive and rising market environment.

One of the primary business strategies adopted by manufacturers in the global Crohn’s disease industry to benefit clients and expand the market sector is to manufacture locally to reduce operating costs. In recent years, Crohn’s disease industry has provided medicine with some of the most significant benefits. The Crohn’s disease market major player such as Johnson & Johnson Services Inc, Pfizer Inc, Allergan, AbbVie Inc, Bayer AG, Amgen Inc and Takeda Pharmaceutical Company Limited.

Founded in 2013, the American biopharmaceutical business AbbVie is publicly traded. It began as an Abbott Laboratories spin-off. A biopharmaceutical firm, which AbbVie founded, combines the focus and culture of a biotech with the stability, global reach, resources, and commercial capabilities of a pharmaceutical company. Its goal is to find and distribute cutting-edge medications and technologies that improve people's lives now, address medical problems of the future, and address critical health crises.

In June 2022, as the first and only selective interleukin-23 (IL-23) inhibitor for the treatment of people with moderately to highly active Crohn's disease, AbbVie Inc., a biopharmaceutical company, announced that the FDA had authorised SKYRIZI (risankizumab-rzaa) (CD).

Also, an international pharmaceutical firm with some American and British heritage, The Takeda Pharmaceutical Company Limited is based in Japan. It is among the top 20 pharmaceutical firms in the world by revenue and is the largest pharmaceutical company in Asia (top 10 following its merger with Shire). The corporation has around 49,578 people worldwide, and its sales for the 2018 fiscal year was US$19,299 billion. Oncology, uncommon illnesses, neuroscience, gastrointestinal, plasma-derived medicines, and vaccines are the company's main areas of interest. Its corporate office is at Nihonbashi, Chuo, Tokyo, while its main office is in Chuo-ku, Osaka.

In April 2022, to broaden an existing agreement to cover the discovery and creation of brand-new therapies for fibrostenotic inflammatory bowel diseases, including Crohn's disease, Engitix and Takeda worked together.